Generic Name and Formulations:
Laronidase 0.58mg/mL; soln for IV infusion after dilution; preservative-free.
Sanofi Genzyme Company
Indications for ALDURAZYME:
For the treatment of Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms.
Adults and Children:
<6 months: not recommended. ≥6 months: Pretreat with antipyretics and/or antihistamines 60mins prior to starting infusion. Give by IV infusion over 3–4hrs. Initial infusion rate: 10mcg/kg/hr, may be increased every 15min during the 1st hour, as tolerated, until max rate of 200mcg/kg/hr which is maintained for the remainder of infusion (2–3hrs). 0.58mg/kg once weekly.
Discontinue immediately if severe anaphylactic or allergic reactions develop; have appropriate medical support measures available. Compromised respiratory function or acute respiratory disease: increased risk of infusion-related reactions. Labor & delivery. Pregnancy (Cat.B). Nursing mothers.
Recombinant human alpha-L-iduronidase enzyme.
Rash, upper respiratory tract infection, inj site reaction, hyperreflexia, paresthesia, flushing, poor venous access, pyrexia, chills, increased BP, tachycardia, decreased oxygen saturation.
Visit www.MPSIregistry.com or call (800) 745-4447 to enroll pregnant women with MPS I.
Single-use vial (5mL)—1
Neurology Advisor Articles
- Combined Exercise Training Increases BDNF in Relapsing-Remitting MS
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Apheresis Associated With Clinical Improvement in Early Active Multiple Sclerosis
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Surgical Outcomes Associated With Trigger Site Deactivation for Migraines
- A Convenient Truth: The Problem With Seizure Under-Reporting and How to Fix It
- Incidence of Serotonin Syndrome With Co-Prescription of Triptans, Antidepressants
- Idiopathic Parkinson Disease May Increase Risk for Overactive Bladder
- Palliative Care in Movement Disorders: Recommendations for Improvement
- Cannabinoids May Be Effective as Adjunctive Treatment for Refractory Epilepsy